Sermorelin – Comprehensive Research Overview (2026)
Sermorelin is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29). It is the shortest fully active fragment of GHRH and was the first GHRH analog to receive FDA approval (for pediatric GH deficiency, now discontinued). Sermorelin stimulates the pituitary gland to produce and release endogenous growth hormone in a physiologic, pulsatile manner, making it one of the most studied and trusted tools in GH axis research.
→ View Sermorelin (for laboratory research use only)
Chemical Structure and Properties
- Amino Acid Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
- Molecular Weight: ≈3,358 Da
- Form: Lyophilized powder for subcutaneous injection
- Key Feature: Shortest fully active GHRH fragment; preserves natural pulsatile GH release
Mechanism of Action
Sermorelin binds to GHRH receptors on pituitary somatotrophs, activating the cAMP/PKA pathway:
- Stimulates both GH synthesis and pulsatile release.
- Preserves natural somatostatin-mediated feedback, preventing GH excess.
- Works synergistically with GHRPs (e.g., Ipamorelin, GHRP-2) for amplified output.
- Shorter half-life than modified analogs, requiring more frequent dosing.
Clinical Evidence and Research Findings
Sermorelin has the most established clinical history of any GHRH analog, with FDA approval history and multiple published trials. Studies demonstrate consistent GH and IGF-1 elevation, improvements in body composition, sleep quality, and bone density. It is widely used in anti-aging and hormone optimization medicine under physician supervision.
→ Interested in researching Sermorelin? View Product Options
Benefits (Research & Clinical Observations)
- Increased lean muscle mass and strength
- Enhanced fat loss and improved body composition
- Improved sleep quality and recovery
- Better bone mineral density
- Support for overall vitality and anti-aging research
- Physiologic GH release with preserved feedback mechanisms
Typical Dosing Protocols (Off-Label / Compounded)
- Common protocols: 200–500 μg subcutaneous once daily (typically at bedtime)
- Some protocols use 100–200 μg 2–3× daily for more frequent pulsing
- Popular stack: Sermorelin + Ipamorelin for synergistic GH output
- Cycles: 3–6 months on, with periodic breaks
Safety Profile and Side Effects
Sermorelin has one of the best-established safety profiles among GHRH analogs.
Common side effects:
- Mild injection-site reactions (flushing, redness)
- Possible mild water retention
- Transient headache or dizziness
Monitoring recommended: IGF-1, fasting glucose, and insulin sensitivity with prolonged use. Contraindicated in active cancer or uncontrolled endocrine disorders.
Sermorelin vs CJC-1295 no DAC vs Tesamorelin – Quick Comparison
| Aspect | Sermorelin | CJC-1295 no DAC | Tesamorelin |
|---|---|---|---|
| Half-life | ~10–20 min | ~30 min | ~26–38 min |
| GH Pattern | Pulsatile | Pulsatile | Pulsatile |
| Clinical History | Extensive (FDA approved) | Moderate | FDA approved (HIV lipodystrophy) |
| Best For | Anti-aging, GH deficiency | Stacking, pulsing | Visceral fat reduction |
| FDA Status | Discontinued approval | Not approved | Approved (specific use) |
FAQ – Frequently Asked Questions
Was Sermorelin FDA approved? Yes, historically for pediatric GH deficiency (as Geref), though this approval was discontinued. It remains available through compounding pharmacies.
How does Sermorelin compare to CJC-1295? Sermorelin has a shorter half-life and more established clinical history. CJC-1295 no DAC offers similar pulsing with slightly better stability.
Can Sermorelin be used alone? Yes, but stacking with a GHRP like Ipamorelin amplifies GH output significantly.
How long until results are seen? IGF-1 rises within weeks; noticeable improvements in sleep, recovery, and body composition typically appear within 4–8 weeks.
Is Sermorelin safe long-term? It has one of the best long-term safety profiles among GHRH analogs, though monitoring is still recommended.
Summary
Sermorelin is the gold-standard GHRH analog with the most established clinical history, offering physiologic pulsatile GH stimulation with an excellent safety profile. It is widely used in anti-aging and hormone optimization research. As with all compounds in this library, Sermorelin is not currently an approved drug for general use and should only be considered under qualified medical supervision with appropriate lab monitoring.
For Laboratory Research Use View Sermorelin →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.